Efficacy of paclitaxel for injection(albumin-bound)combined with cisplatin in the treatment of advanced non-small-cell lung cancer
Objective To explore the efficacy of paclitaxel for injection(albumin-bound)combined with cisplatin in the treatment of advanced non-small-cell lung cancer(NSCLC).Methods A total of 88 patients with advanced NSCLC were selected and divided into an observation group and a control group according to random number table method,each with 44 cases.The control group was given gemcitabine and cisplatin chemotherapy regimen,and the observation group was given paclitaxel for injection(albumin-bound)and cisplatin chemotherapy regimen.Patients in both groups wree compared in terms of clinical efficacy,levels of serum tumor markers[cytokeratin fragment 19(CYFRA21-1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]and the occurrence of adverse reactions.Results After treatment,the objective response rate(ORR)of 59.09%and disease control rate(DCR)of 79.55%in the observation group were significantly better than 36.36%and 54.55%in the control group(P<0.05).There were no significant differences in CYFRA21-1,CA125 and CEA between the two groups before treatment(P>0.05).After treatment,CYFRA21-1,CA125 and CEA were decreased in both groups compared with those before treatment;the falling amplitude of CYFRA21-1,CA125 and CEA in the observation group were more significant than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 11.36%,which was lower than 36.36%in the control group(P<0.05).Conclusion Paclitaxel for injection(albumin-bound)and cisplatin chemotherapy regimen has a definite effect on advanced NSCLC patients,can significantly alleviate clinical symptoms,and the incidence of adverse reactions is low,which is worthy of clinical wide application.
Paclitaxel for injection(albumin-bound)CisplatinAdvanced non-small-cell lung cancerAdverse reactions
万方数据
维普
